Answers are grounded in this paper and cite their sources.
Pancreaticobiliary carcinomas rarely harbor targetable genetic alterations, including microsatellite instability (MSI) or neurotrophic tyrosine receptor kinase (NTRK) gene fusions. As these malignancies are typically present at an advanced stage and have suboptimal response to chemotherapy, the discovery of an actionable genomic alteration provides an additional avenue of treatment for chemotherapy-refractory cases.
No takes yet. Share an insight, caveat, or question.
Connelly et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: